EP1496923A4 - Immunotherapie du cancer - Google Patents

Immunotherapie du cancer

Info

Publication number
EP1496923A4
EP1496923A4 EP02723576A EP02723576A EP1496923A4 EP 1496923 A4 EP1496923 A4 EP 1496923A4 EP 02723576 A EP02723576 A EP 02723576A EP 02723576 A EP02723576 A EP 02723576A EP 1496923 A4 EP1496923 A4 EP 1496923A4
Authority
EP
European Patent Office
Prior art keywords
cancer immunotherapy
immunotherapy
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02723576A
Other languages
German (de)
English (en)
Other versions
EP1496923A1 (fr
Inventor
Waldemar Debinski
Neil Christensen
Akiva Mintz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Original Assignee
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation filed Critical Penn State Research Foundation
Publication of EP1496923A1 publication Critical patent/EP1496923A1/fr
Publication of EP1496923A4 publication Critical patent/EP1496923A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001119—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP02723576A 2002-03-22 2002-03-22 Immunotherapie du cancer Withdrawn EP1496923A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/008983 WO2003092717A1 (fr) 2002-03-22 2002-03-22 Immunotherapie du cancer

Publications (2)

Publication Number Publication Date
EP1496923A1 EP1496923A1 (fr) 2005-01-19
EP1496923A4 true EP1496923A4 (fr) 2005-10-19

Family

ID=29398905

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02723576A Withdrawn EP1496923A4 (fr) 2002-03-22 2002-03-22 Immunotherapie du cancer

Country Status (5)

Country Link
EP (1) EP1496923A4 (fr)
JP (1) JP2005526842A (fr)
AU (1) AU2002254348B2 (fr)
CA (1) CA2480008C (fr)
WO (1) WO2003092717A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228369A1 (en) * 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
CA2700573C (fr) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Vaccins comprenant des antigenes de cellules souches cancereuses et procedes
WO2008039969A2 (fr) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Vaccins contre le cancer et méthodes de vaccination
US20100291677A1 (en) * 2007-08-24 2010-11-18 Keio University Reducer of immunosuppression by tumor cell and antitumor agent using the same
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
WO2014127296A1 (fr) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Vaccins contre le cancer et méthodes de vaccination
CN117801069A (zh) * 2016-10-07 2024-04-02 恩特罗姆公司 用于癌症疗法的免疫原性化合物
IL296165B2 (en) 2016-10-07 2023-10-01 Enterome S A Immunogenic compounds for cancer treatment
US11712465B2 (en) 2016-10-07 2023-08-01 Enterome S.A. Microbiota sequence variants of tumor-related antigenic epitopes
EP3480212B1 (fr) 2017-11-03 2023-09-27 Consejo Superior De Investigaciones Científicas Peptide il13ralpha2 et ses utilisations
ES2935702T3 (es) 2018-04-11 2023-03-09 Enterome S A Péptidos antigénicos para la prevención y el tratamiento del cáncer
CA3173893A1 (fr) * 2020-05-15 2021-11-18 Di YU Anticorps anti-il13r.alpha.2, fragments de liaison a l'antigene et utilisations associees
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058479A1 (fr) * 2000-02-08 2001-08-16 The Penn State Research Foundation Utilisation du recepteur de l'interleukine 13, sous-unite alpha 2, dans l'immunotherapie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058479A1 (fr) * 2000-02-08 2001-08-16 The Penn State Research Foundation Utilisation du recepteur de l'interleukine 13, sous-unite alpha 2, dans l'immunotherapie

Also Published As

Publication number Publication date
EP1496923A1 (fr) 2005-01-19
WO2003092717A1 (fr) 2003-11-13
CA2480008A1 (fr) 2003-11-13
AU2002254348B2 (en) 2007-12-06
AU2002254348A1 (en) 2003-11-17
CA2480008C (fr) 2015-10-06
JP2005526842A (ja) 2005-09-08

Similar Documents

Publication Publication Date Title
GB2391392B (en) Co-located atennas
IL166084A0 (en) Novel benzodioxoles
PL371678A1 (en) Novel pyridin- and pyrimidin-derivatives
PL373598A1 (en) Novel benzonaphthyridines
EP1482970A4 (fr) Therapie anticancereuse
ZA200408427B (en) Adjuvant enhanced immunotherapy
GB0228900D0 (en) Cancer Immunotherapy
IL163529A0 (en) Novel spinosyn-producing polyketidesynthases
GB0207362D0 (en) Chemotherapy
GB0208516D0 (en) Chemotherapy
AU2003264488A1 (en) Immunotherapeutic for cancer
GB0223696D0 (en) Improved immunotherapy
GB0220658D0 (en) Immunotherapy
GB0225750D0 (en) Wiffs away
GB0226595D0 (en) Cancer therapy determination
EP1587405A4 (fr) Nouvelles compositions et procedes de traitement du cancer
GB0200110D0 (en) Cancer detection
GB0208585D0 (en) Holelock
GB2383538B (en) Cancer treatment
GB0229743D0 (en) Novel benzoxazocines
GB0218725D0 (en) Cancer related methods
GB2375065B (en) Sharpening means
GB0215011D0 (en) Easy squeezy
GB0213950D0 (en) Bannistair slide
GB0212663D0 (en) Bannistair slide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041019

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050905

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 35/00 B

Ipc: 7C 07K 7/00 B

Ipc: 7C 07K 4/00 B

Ipc: 7C 07K 2/00 B

Ipc: 7C 07K 1/00 B

Ipc: 7C 07K 17/00 B

Ipc: 7C 07K 16/00 B

Ipc: 7C 07K 14/00 B

Ipc: 7A 01K 43/04 B

Ipc: 7A 61K 31/70 B

Ipc: 7A 61K 39/00 B

Ipc: 7A 61K 38/00 A

17Q First examination report despatched

Effective date: 20060424

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071204